ABSTRACT

Metformin HCl (MET) and Remogliflozin Etabonate (REM) is a new drug combination used for treating diabetes mellitus. It is necessary to estimate the drugs in the combined dosage form. For the simultaneous quantification of metformin HCl and remogliflozin etabonate, high-performance thin layer chromatography (HPTLC) was devised in the current investigation. For separation Merck pre-coated silica gel aluminium plate 60 F254 was used as stationary phase and Acetone: methanol: chloroform: Formic acid (3: 1: 5: 1) as mobile phase. A camag TLC scanner was used to densitometrically scan plates at 224 nm to quantify the medication. The method has been tested for linearity, precision, accuracy, and robustness by ICH criteria. The response was found linear over the concentration range of 100-600ng/band with a regression value of 0.999 for both the drugs. Metformin's LOD and LOQ were reported to be 5.34 and 17.81 ng/band, but remogliflozin's LOD and LOQ were reported to be 11.03 and 33.45 ng/band. This method can be used for its intended purpose because they are highly sensitive, accurate and precise. Keywords: Metformin HCl, Remogliflozin etabonate, Validation, Densitometric, High- Performance Thin Layer chromatography
Publication date: 01/08/2023

https://ijbpas.com/pdf/2023/August/MS_IJBPAS_2023_7364.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2023/12.8.7364